Evaluating liver embolization techniques for tumor management

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the short, medium, and long-term outcomes of various embolization techniques in patients with primary and secondary liver tumors. It focuses on assessing progression-free survival following embolization and the residual hepatic volume in cases where these techniques are used to promote liver regeneration. Patients will continue their standard treatment protocols without any additional interventions specific to the study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ≥ 18 yoa
* patients with patients with primary or secondary liver disease not amenable for surgery or ablation
* patients with primary or secondary liver tumors candidates for major surgery prior to induction of hypertrophy
* able and willing to sign informed consent

Exclusion Criteria:

* pregnant women
* patients with uncorrectable coagulopathy
* diffuse extrahepatic disease
* for lobar TACE and TARE - presence of bilodigestive shunt
* for TARE - \>20% hepatopulmonary shunt

Where it's running

• IRCCS Ospedale San Raffaele
  Milan, Italy Recruiting

Study contacts

• Study coordinator: Francesco De Cobelli, MD
• Email: trialcliniciradiologia@hsr.it
• Phone: +39022643

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Liquid biopsy to differentiate types of primary liver cancer

  This study is testing a new blood test to see if it can tell the difference between two types of liver cancer, hepatocellular carcinoma and intrahepatic cholangiocarcinoma, to help doctors diagnose patients more safely.

  Recruiting at 5 sites City of Hope Medical Center · Duarte, California and 4 other locations · NCT06342414

• 68Ga-SorB PET/CT imaging for solid tumors

  This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07760012

• Using contrast-enhanced ultrasound to check Y-90 radioembolization response in liver cancer

  This will test whether contrast-enhanced ultrasound (CEUS) can show treatment response to Y‑90 radioembolization in people with newly diagnosed hepatocellular carcinoma who are scheduled for TARE.

  Recruiting Phase 2 Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07145801

• Combining portal and hepatic vein embolization for liver cancer treatment

  This study is testing if combining two types of vein treatments can help more people with liver cancer have surgery and live longer.

  Recruiting Maastricht University · New Haven, Connecticut and 54 other locations · NCT06914648

• Assessing blood biomarkers and MRI for liver cancer patients undergoing radiation therapy

  This study is testing if using special MRI scans and blood tests can help doctors keep track of liver health in patients with liver cancer who are getting radiation therapy.

  Recruiting Montefiore Medical Center · The Bronx, New York · NCT06899152

• Using a new imaging agent to detect various cancers

  This study is testing a new imaging agent to see if it can better detect certain cancers in adults compared to standard imaging methods.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06503146

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.